Immunologically inert nanostructures as selective therapeutic tools in inflammatory diseases

Laura Talamini, Eiji Matsuura, Luisa De Cola, Sylviane Muller

Research output: Contribution to journalReview articlepeer-review

3 Citations (Scopus)


The current therapies based on immunosuppressant or new biologic drugs often show some limitations in term of efficacy and applicability, mainly because of their inadequate targeting and of unwanted adverse reactions they generate. To overcome these inherent problems, in the last decades, innovative nanocarriers have been developed to encapsulate active molecules and offer novel promising strategies to efficiently modulate the immune system. This review provides an overview of how it is possible, exploiting the favorable features of nanocarriers, especially with regard to their immunogenicity, to improve the bioavailability of novel drugs that selectively target immune cells in the context of autoimmune disorders and inflammatory diseases. A focus is made on nanoparticles that selectively target neutrophils in inflammatory pathologies.

Original languageEnglish
Article number707
Issue number3
Publication statusPublished - Mar 2021


  • Drug targeting
  • Immunomodulation
  • NETosis
  • Nanoparticles
  • Neutrophils
  • Therapeutic carriers

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Immunologically inert nanostructures as selective therapeutic tools in inflammatory diseases'. Together they form a unique fingerprint.

Cite this